Clinical nuclear medicine · 2025
Prognostic Value of A/T/N Biomarkers: Comparing Plasma and Imaging Modalities in Alzheimer Disease.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yim Sohyun, Gu Yuna, Kang Heekyung, Shin Daeun, Jang Hyemin, Yoo Heejin, Zetterberg Henrik, Blennow Kaj, Gonzalez-Ortiz Fernando, Ashton Nicholas J, Weiner Michael W, Day Theresa A, Lee Eun Hye, Na Duk L, Kim Hee Jin, Kang Sung Hoon, Kim Ko Woon, Kim Yeo Jin, Kim Yeshin, Kim Jaeho, Chun Min Young, Jung Na Yeon, Cho Soo Hyun, Kim Jun Pyo, Yun Jihwan, Seo Sang Won, K-ROAD study groups
Аннотация
BACKGROUND: Alzheimer disease (AD) is characterized by amyloid-β plaques (A), tau tangles (T), and neurodegeneration (N), collectively defining the ATN framework. While imaging biomarkers are well-established, the prognostic value of plasma biomarkers in predicting cognitive decline remains underexplored. This study compares plasma and imaging A/T/N biomarkers in predicting cognitive decline and evaluate the impact of combining biomarkers across modalities.
PATIENTS AND METHODS: We conducted a longitudinal study using K-ROAD cohort participants who underwent at least 2 cognitive assessments. All participants had plasma biomarker testing (Aβ ratio, p-tau181, p-tau231, p-tau217, NfL), and a subset with imaging biomarker assessments (Aβ PET, tau PET, structural MRI) formed an imaging subcohort. Multiple linear regression models identified the most predictive markers within each modality and evaluated the effect of combining A/T/N biomarkers.
RESULTS: Among 1,614 plasma cohort and 130 imaging subcohort participants, tau markers demonstrated the strongest predictive value. p-tau217 MSD outperforming other plasma biomarkers, and the neo-temporal ROI showing the highest predictive power among imaging biomarkers. In plasma-based model, adding neurodegeneration markers to combination of amyloid and tau biomarkers improved the performance. In imaging-based models, same strategy decreased the performance, suggesting that combinations of amyloid and tau PET captures the most relevant prognostic information.
CONCLUSIONS: Imaging biomarkers, particularly tau PET, show superior prognostic accuracy compared with plasma biomarkers, whereas plasma biomarkers offer advantages in combination models through neurodegeneration markers. These findings underscore the complementary roles of plasma and imaging biomarkers and emphasize the need for tailored strategies for prognostic modeling in AD.
PATIENTS AND METHODS: We conducted a longitudinal study using K-ROAD cohort participants who underwent at least 2 cognitive assessments. All participants had plasma biomarker testing (Aβ ratio, p-tau181, p-tau231, p-tau217, NfL), and a subset with imaging biomarker assessments (Aβ PET, tau PET, structural MRI) formed an imaging subcohort. Multiple linear regression models identified the most predictive markers within each modality and evaluated the effect of combining A/T/N biomarkers.
RESULTS: Among 1,614 plasma cohort and 130 imaging subcohort participants, tau markers demonstrated the strongest predictive value. p-tau217 MSD outperforming other plasma biomarkers, and the neo-temporal ROI showing the highest predictive power among imaging biomarkers. In plasma-based model, adding neurodegeneration markers to combination of amyloid and tau biomarkers improved the performance. In imaging-based models, same strategy decreased the performance, suggesting that combinations of amyloid and tau PET captures the most relevant prognostic information.
CONCLUSIONS: Imaging biomarkers, particularly tau PET, show superior prognostic accuracy compared with plasma biomarkers, whereas plasma biomarkers offer advantages in combination models through neurodegeneration markers. These findings underscore the complementary roles of plasma and imaging biomarkers and emphasize the need for tailored strategies for prognostic modeling in AD.